Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients

Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients

There are limited data of amikacin pharmacokinetics (PK) in the elderly population. Hence, we aimed to describe the population PK of amikacin in elderly patients (>70 years old) and to establish optimized initial dosing regimens. We simulated individual maximum concentrations in plasma (Cmax) and...

Full description

Bibliographic Details
Main Authors:	Hideo Kato, Suzanne L. Parker, Jason A. Roberts, Mao Hagihara, Nobuhiro Asai, Yuka Yamagishi, David L. Paterson, Hiroshige Mikamo
Format:	Article
Language:	English
Published:	MDPI AG 2021-01-01
Series:	Antibiotics
Subjects:	population pharmacokinetics analysis amikacin elderly <i>Pseudomonas aeruginosa</i>
Online Access:	https://www.mdpi.com/2079-6382/10/2/100

Similar Items

Clinical Pharmacokinetics of Amikacin in Neonates
by: Gian Maria Pacifici, et al.
Published: (2017-02-01)

Efficacy of intraventricular amikacin treatment in pan-resistant Pseudomonas aeruginosa postsurgical meningitis
by: Molinaro M, et al.
Published: (2018-09-01)

Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant <i>Pseudomonas aeruginosa</i>
by: Sara Mahmoud Farhan, et al.
Published: (2021-11-01)

Effect of mannitol on the pharmacokinetics of amikacin in wistar rats
by: Hugo Juárez Olguín, et al.
Published: (2009-08-01)

The comparative effects of erythromycin and amikacin on acute respiratory Pseudomonas aeruginosa infection
by: Mohsen Yazdanian, et al.
Published: (2023-03-01)

The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection
by: Yuhang Wang, et al.
Published: (2022-10-01)

Review on Population Pharmacokinetics of Amikacin in Paediatrics
by: Keerthana Chandrasekar, et al.
Published: (2022-12-01)

Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model
by: Minyon L. Avent, et al.
Published: (2022-06-01)

Metabolomics reveals the mechanism of action of meropenem and amikacin combined in the treatment of Pseudomonas aeruginosa
by: Hai Yang, et al.
Published: (2023-12-01)

Initial In Vivo Evaluation of a Novel Amikacin-Deoxycholate Hydrophobic Salt Delivers New Insights on Amikacin Partition in Blood and Tissues
by: Styliani Xiroudaki, et al.
Published: (2021-01-01)

Glucose-Potentiated Amikacin Killing of Cefoperazone/Sulbactam Resistant Pseudomonas aeruginosa
by: Xi-kang Tang, et al.
Published: (2022-03-01)

Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects
by: Antoni Torres, et al.
Published: (2018-12-01)

Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease
by: Xuanyou Jin, et al.
Published: (2020-11-01)

Profil Farmakokinetik Amikasin Pemberian Intravena Melalui Vena Sublingualis dan Coccygea pada Ular Sanca Batik (PHARMACOKINETIC PROFILE OF AMIKACIN ADMINISTERED INTRA VENOUSLY VIA SUBLINGUAL AND COCCYGEA VEINS IN BROGHAMMERUS RETICULATUS)
by: Agustina Dwi Wijayanti, et al.
Published: (2014-05-01)

Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model
by: Jessica R. Tait, et al.
Published: (2022-01-01)

Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation
by: Claire Pressiat, et al.
Published: (2022-01-01)

Combination Therapy of Polymyxin B and Amikacin for Community-Acquired Pseudomonas aeruginosa Pneumonia with MODS in a Previously Healthy Patient: A Case Report
by: Wang J, et al.
Published: (2021-07-01)

Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of Refractory <i>Mycobacterium avium</i> Complex Pulmonary Disease
by: Bo-Guen Kim, et al.
Published: (2020-09-01)

In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae
by: Wei Yu, et al.
Published: (2017-06-01)

Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia
by: Ana Motos, et al.
Published: (2023-02-01)

Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergence
by: Joy E. Gibson, et al.
Published: (2024-02-01)

Development of a Predictive Dosing Nomogram to Achieve PK/PD Targets of Amikacin Initial Dose in Critically Ill Patients: A Non-Parametric Approach
by: Anne Coste, et al.
Published: (2023-01-01)

Enhanced effect of Amikacin in conjugation with gold nanopartcles as a carrier to kill Pseudomonas aeruginosa
by: Afsaneh Emameian, et al.
Published: (2020-12-01)

Therapeutic Drug Monitoring of Amikacin in Neutropenic Oncology Patients
by: Maria Aquino, et al.
Published: (2023-02-01)

Analysis of Phenotypic and Genotypic Susceptibility to Clarithromycin and Amikacin of <i>Mycobacterium abscessus</i> Complex Strains Isolated from Cystic Fibrosis Patients
by: Juan Carlos Cao Yao, et al.
Published: (2023-11-01)

Intrathecal use of amikacin: a case report
by: L. Barrou, et al.

Comparative Study between Combined Intravenous and Nebulized Amikacin versus Intravenous Amikacin Alone for Treatment of Ventilator Associated Pneumonia
by: Sameh Seyam, et al.
Published: (2022-06-01)

A Systematic Review and Meta-Analysis of Efficacy and Safety of Azithromycin Versus Moxifloxacin for the Initial Treatment of <i>Mycoplasma genitalium</i> Infection
by: Hideo Kato, et al.
Published: (2022-03-01)

High-dose amikacin for achieving serum target levels in critically ill elderly patients
by: Sadeghi K, et al.
Published: (2018-02-01)

Concentration-Dependent Activity of Pazufloxacin against <i>Pseudomonas aeruginosa</i>: An In Vivo Pharmacokinetic/Pharmacodynamic Study
by: Yasuhiro Umezaki, et al.
Published: (2022-07-01)

Protective effect of creatine on amikacin-induced ototoxicity
by: Emre Apaydın, et al.
Published: (2022-09-01)

Predictors of insufficient peak amikacin concentration in critically ill patients on extracorporeal membrane oxygenation
by: Cyril Touchard, et al.
Published: (2018-08-01)

Intermittent Short-Term Infusion vs. Continuous Infusion of Piperacillin: Steady State Concentrations in Porcine Cervical Spine Tissue Evaluated by Microdialysis
by: Elisabeth Krogsgaard Petersen, et al.
Published: (2022-07-01)

Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
by: María M. Montero, et al.
Published: (2021-09-01)

Effect of Gold Nanostars Plus Amikacin against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Biofilms
by: John Jairo Aguilera-Correa, et al.
Published: (2022-01-01)

Necrotizing pneumonia due to Pseudomonas aeruginosa secondary to severe COVID‐19 pneumonia
by: Jun Hirai, et al.
Published: (2023-04-01)

Evaluation of Current Amikacin Dosing Recommendations and Development of an Interactive Nomogram: The Role of Albumin
by: Jonás Samuel Pérez-Blanco, et al.
Published: (2021-02-01)

A New Framework to Implement Model-Informed Dosing in Clinical Guidelines: Piperacillin and Amikacin as Proof of Concept
by: Stan J. F. Hartman, et al.
Published: (2020-12-01)

The Direction of the Antibacterial Effect of Rutin Hydrate and Amikacin
by: Maria Miklasińska-Majdanik, et al.
Published: (2023-09-01)

Intraperitoneal Amikacine Provoked Perceptive Deafness in CAPD - Continuous Ambulatory Peritoneal Dialysis Patient
by: Lutfi Zylbeari, et al.
Published: (2020-07-01)